Palvella Therapeutics PVLA Payments Of Merger Related Costs Financing Activities
Payments Of Merger Related Costs Financing Activities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's payments of merger related costs financing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's payments of merger related costs financing activities?
- Palvella Therapeutics (PVLA) reported payments of merger related costs financing activities of $0 in Q1 2026.
- How has Palvella Therapeutics's payments of merger related costs financing activities changed year-over-year?
- Palvella Therapeutics's payments of merger related costs financing activities decreased by 100.0% year-over-year, from $1.27M to $0.
- What does payments of merger related costs financing activities mean?
- Captures the cash outflows associated with professional fees, advisory services, and other transaction costs incurred during a merger or acquisition process. These payments are classified as financing activities when they relate to the capital structure or issuance of securities. Monitoring these costs is important for evaluating the total capital expenditure required to execute corporate growth strategies.